CCR FOCUS Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors
نویسندگان
چکیده
Gastrointestinal stromal tumors (GIST) are the most common type of sarcoma in the Auth Scien Rece 12/15 Gran
منابع مشابه
CCR 20th Anniversary Commentary: A Genetic Mechanism of Imatinib Resistance in Gastrointestinal Stromal Tumor-Where Are We a Decade Later?
In the June 1, 2005, issue of Clinical Cancer Research, Antonescu and colleagues defined second-site KIT mutations in gastrointestinal stromal tumor (GIST) as the leading mechanism of acquired resistance to imatinib. Secondary mutations were detectable mainly in KIT exon 11 mutant GISTs after prolonged initial clinical responses. These findings played a critical role in designing the next gener...
متن کاملWhy tyrosine kinase inhibitor resistance is common in advanced gastrointestinal stromal tumors [version 1; referees: 2 approved]
Most patients with advanced gastrointestinal stromal tumors Background: (GIST) develop drug resistance to tyrosine kinase inhibitors (TKIs) within two years of starting therapy, whereas most chronic myeloid leukemia (CML) patients in chronic phase still exhibit disease control after a decade on therapy. This article aims to explain this divergence in long term outcomes. By combining clinical an...
متن کاملGastrointestinal Stromal Tumor: A Rare Abdominal Tumor
Gastrointestinal stromal tumors (GISTs) are rare abdominal tumors which arise from the interstitial cells of Cajal in the gastrointestinal tract. Gastric GISTs are the most commonly seen GIST tumors and may grow to a very large size. They are often associated with abdominal pain, anorexia and weight loss. Most of them can be detected by CT. These tumors have been found to harbor mutations in CD...
متن کاملDetermination of CD117 Expression in Glial Tumors and Its Comparison between High Grade and Low Grade Tumors
Background and Objective: Gliomas are the most common primary brain tumors. Despite therapeutic advances, the majority of gliomas do not respond to either chemo or radiotherapy. CD117, the gene product of c-kit has been expressed in cells of glial tumors. Because gastrointestinal stromal tumors (GISTs) that express CD117 respond dramatically to treatment with tyrosine kinase inhibitors, ide...
متن کاملWhy tyrosine kinase inhibitor resistance is common in advanced gastrointestinal stromal tumors
BACKGROUND Most patients with advanced gastrointestinal stromal tumors (GIST) develop drug resistance to tyrosine kinase inhibitors (TKIs) within two years of starting therapy, whereas most chronic myeloid leukemia (CML) patients in chronic phase still exhibit disease control after a decade on therapy. This article aims to explain this divergence in long term outcomes. METHODS AND RESULTS By ...
متن کامل